Pharmeasy Share Company Essentials
ISIN NUMBER
INE0DJ201029
Lot Size
500 shares
Demat Status
CDSL, NSDL
NET PROFIT
₹ -641 Cr
FACE VALUE
₹ 1/share
Current Ratio
3.67
All Time High
₹ 135
PharmEasy Unlisted Share Price
₹ 11/Share
ROE
-33.51%
Cashflow from Operations
₹ -813 Cr.
Market Cap
INR 15,972 Cr.
NET REVENUE
₹ 2360 Cr.
About Pharmeasy Share
- Incorporated on March 31, 2019, the company is India’s largest digital healthcare platform (based on GMV of products and services sold for the year ended March 31, 2021), according to RedSeer Report.
API Holdings operates an integrated, end-to-end business that aims to provide solutions for the healthcare needs of consumers across the following critical stages:
- providing digital tools and information on illness and wellness.
- offering teleconsultation
- offering diagnostics and radiology tests,
- delivering treatment protocols, including products and devices.
3. The company owns the “PharmEasy” brand, and its proprietary technology platform powers the PharmEasy marketplace. The company has licenced the brand and the technology to Axelia, which is owned by Aarman and in which the company has a 19.99% equity interest. Axelia operates the PharmEasy marketplace.
4.PharmEasy Marketplace had 25 million registered users across India as of June 30, 2021.
5. For the three months ending June 30, 2021, API Holding’s platform had 87,194 pharmacies, 3,261 wholesalers, 4,617 doctors, and 926 hospitals.
6. The journey of API holdings can be seen in this infographic:
Market Statistics:
- The Indian Healthcare market is projected to reach INR 20 Trillion by 2025.
Pharmeasy Share IPO Details
The company had previously filed a DRHP, but it withdrew its IPO plans. There are no updates relating to Pharmeasy’s IPO as of now.
Pharmeasy share price is trading in the range of Rs. 18-20 in the unlisted market
Pharmeasy Share Price
Pharmeasy share price is decided on the basis of it’s funding round that it raised from it’s investors. After that, price is decided by the forces of demand and supply as same as listed market. Pharmeasy share price is Rs 18 per share with a face value of Rs 10.
Business Segment of Pharmeasy Company.
The Pharmeasy online marketplace constantly updates customers easily about their services and provides an online platform as a means of providing security in order to win over the trust of various customers. This platform runs in a specific way in order to make sure that the services and medications it provides are of the best possible quality and delivered on time.
The customer gives the company their prescription information as the first step in the PharmEasy business plan. This prescription is checked using a certain set of parameters before being given to a nearby pharmacy for the customer’s use.
With different partnerships and with multiple authorized pharmacies, PharmEasy is able to evaluate prescriptions, necessary medications, and other advantages related to the medication. Next, according to the rules and regulations, a transport agency will pick up the prescription and the medications so that the pharmacy can verify and check them. In some circumstances, if the pharmacist has any questions related to the prescription, they can get in touch with you as well. Once the purchase has been verified and checked, it is sent out for delivery.
Strengths of Pharmaeasy Company
With the advancement of technology in today’s world, it has increased the usage of internet, many people now find it extremely simple and easy to make purchases online. It’s beneficial for companies like PharmEasy, which has operated online from the day it was founded, particularly in view of the epidemic and many other businesses that have moved online.
- Growing Use of Mobile Healthcare Options: It is now possible to exchange information with just a few swipes of the fingertips thanks to the development of healthcare operating platforms and apps. Solutions for mobile health are developing fastly as it becomes more and more prevalent.
- Payment Methods: Time-saving and easy and simple methods of payment.
- Less Expensive: Because there are a number of retailers in the selling of medicines process, physical shop pharmacies are more expensive. By selling in bulk online, online virtual pharmacies will lower the price of medications.
- Easy to use and User-Friendly: PharmEasy makes it possible for customers to buy medicines with only a few fingertip clicks, making the entire process extremely simple and easy to use.
Pharmeasy Peers
PharmEasy is India’s largest digital healthcare platform based on gross merchandise value (GMV). It is all set to make its debut on the stock exchanges. There are many existing businesses in the listed sectors that are venturing into digital healthcare. Here’s a look at PharmEasy’s competitors in the stock markets.
Top 5 PharmEasy competitors
- 1mg
- SastaSundar
- Medlife International
- Netmeds
- eVital
Market Peers
Competitors | Market Capitalisation |
MedPlus | ₹ 7,877 crore |
SBI Life Insurance | ₹ 1,073 crore |
Pharmeasy Valuation and Analysis
Funding History of Pharmeasy
Launched in 2014, PharmEasy received angel funding in 2015; After that, its founders participated in a series of funding rounds. With the Series A round of funding, the company focused on expanding its business to five cities and launched a home diagnostic service. Following the funding round, PharmEasy covered over 700 cities and launched its online healthcare product and service platform, which received a massive response from customers.
In 2020 and 2021, PharmEasy merged with Ascent Health and other companies to form a parent company called API Holding Limited. After that, it acquired a 66% stake in Thyrocare and became the first unlisted company to buy shares of a listed company. Here are PharmEasy’s funding details over the years:
March 2016 | 34 Crores |
March 2017 | 104 Crores |
April 2017 | 13 Crores |
February 2018 | 350 Crores |
September 2018 | 2800 Crores |
September 2018 | 1650 Crores |
November 2019 | 2400 Crores |
April 2021 | 13 Crores |
June 2021 | 150 Crores |
This is not the first time that PharmEasy’s share price has fallen by a significant margin. PharmEasy hit a low in the pre-IPO market a few years ago with its unlisted share price falling by 70%. Let’s take a look at the financial performance of PharmEasy over the last two financial years in the pre-IPO market:
PharmEasy Financial Performance | FY 2021 (Cr.) | FY 2022 (Cr.) |
Net Revenue | 2360 | 5781 |
EBITDA | -569 | -2302 |
OPM | -24.39 | -39 |
Finance Cost | 43 | 238 |
Profit before tax | -620 | -3890 |
Profit After Tax | -641 | -3991 |
EPS | -2 | -7 |
PharmEasy’s current performance in the pre-IPO market largely depends on its financial growth and decline. The company’s expenses also increased from Rs 270 crore to Rs 1549 crore in the last two years. Amid the news of PharmEasy’s IPO, current performance is an important factor in making investment decisions.
According to experts, the estimated growth rate of PharmEasy after the IPO launch will be 30-40%. However, you can buy unlisted shares of PharmEasy before the company gets listed on the stock exchange.
Pharmaeasy's mission and vision
At PharmEasy, our mission is to provide everyone with access to high-quality, excellent healthcare at an affordable price. We follow extremely strict guidelines to make sure that you receive correct and carefully researched healthcare information. Our highly trained staff members, including medical professionals, healthcare providers, chemical professionals, and writers, select and verify all of our information based on research.
Our vision is to gain and continue to grow potential customers while also being among the biggest pharmaceutical companies in India and providing the highest quality guaranteed products in the market. A platform that is easy to use and accessible to all.
Why Should You Buy Unlisted Shares of Pharmeasy?
Investing in unlisted shares of a company is a great way to diversify an investment portfolio and reduce risk. Since PharmEasy is planning to launch its IPO this year, you can enjoy long-term gains by investing early in its unlisted shares. Another reason to invest in unlisted shares of PharmEasy is the low liquidity and high growth opportunity. However, you should consider past and present performance equally when investing in PharmEasy.
The best step is to talk to experts and get their opinion. You can contact our team for the right advice regarding unlisted shares. Stockify is a trusted platform for buying unlisted shares and has a wide range of blue-chip stocks for retail investors. Here, you can easily check the current price of unlisted shares and analyze their performance over the last few years. Find the best-performing unlisted stocks now!
Pharmeasy Share Subsidiaries
- Threpsi Solutions Private Limited;
- Aycon Graph Connect Private Limited;
- ARZT and Health Private Limited;
- Akna Medical Private Limited;
- Docon Technologies Private Limited;
- AHWSPL India Private Limited;
- Instinct Innovations Private Limited;
- Ayro Retail Solutions Private Limited;
- Ascent Wellness and Pharma Solutions Private Limited;
- Avighna Medicare Private Limited;
- D. C. Agencies Private Limited;
- Desai Pharma Distributors Private Limited;
- Eastern Agencies Healthcare Private Limited;
- VPI Medisales Private Limited;
- Aarush Tirupati Enterprise Private Limited;
- AKP Healthcare Private Limited;
- Aryan Wellness Private Limited and many more.
Pharmeasy Share Board Members
Pharmeasy Share Consolidated Results
Profit and Loss Statement
*figures in Cr. execpt EPS
Balance Sheet
*figures in Cr.
Cashflow
*figures in Cr.
Pharmeasy Share News
Is it worth to Buy Unlisted Shares of Pharmeasy?
As mentioned above, PharmEasy is India’s largest digital healthcare platform based on GMV. It is the best platform that offers online medicine, diagnostic tests, and consultations. PharmEasy is a reputed name and it has 25 million registered users and around 87,194 pharmacies, 3,261 wholesalers, 4,617 clinics, prescribing doctors, and 926 hospitals. To manage the workflow and streamline the company’s transactions, the company works on advanced AI/ML.
In the past few years, the unlisted share price of PharEasy (API Holding Ltd.) has seen a significant downfall. It fell from Rs 135 to Rs 22 per share. But the investors are still betting on the company to generate significant returns whereas the ground seems murky for the company’s growth. It is the best way to make a fortune out of the company’s growth, buying unlisted shares of PharmEasy. Investors are continuously buying and selling the unlisted shares of the company to generate profits. According to an estimate, the company has still hope for recovery in the long run because it has seen a growth of 220% in FY 2021. It will be a boom, because of the rising demand for health services and multiple pandemics.
Pharmeasy Share FAQs
PharmEasy’s unlisted share price is only Rs. 13 in India. Even it is India’s leading digital healthcare platform.
Please find below the procedure for buying Pharmeasy Unlisted Shares/Pre-IPO shares at Bharat Invest.
- You confirm booking of Pharmeasy Unlisted Shares/Pre-IPO shares with us at a specified price.
- You have to provide your client master report along with PAN Card and Cancelled Cheque in case you are not transferring funds from the bank account as mentioned in the CMR Copy. These are KYC documents required as per SEBI regulations.
- We will provide our bank details.
- You need to transfer funds in the current account of bharatinvest.
- No cash deposit is accepted
- Payment has to be done from the same account in which shares are to be credited.
- We ensure delivery of Pharmeasy unlisted shares within 24 hours.
- Incase of non-availability of shares, we refund the amount to the same bank account within 24 hours.
- For detailed discussion, you can contact us via any medium.
Please find below the procedure for selling Pharmeasy Unlisted Shares/Pre-IPO shares at Bharat Invest.
- We will confirm our buying price of Pharmeasy Unlisted Shares/Pre-IPO shares.
- We will give you our client master report and you will transfer the Pharmeasy Unlisted Shares/Pre-IPO shares to our demat account.
- We will transfer the funds in your bank account within 24 hours of receiving the Pharmeasy Unlisted Shares/Pre-IPO shares.
- All the transactions will be bank to bank.
- Payment will be given in the same account which is linked to demat account or you need to provide the cancelled cheque shows your name to verify.
- You can contact us through any medium for a detailed discussion.
The lockin period is of 6 months for pre-ipo investors i.e. they cannot sell their shares for 6 months after they get listed. However, they can definitely sell the shares in pre-ipo market before they get listed.
With BharatInvest , you can now invest in unlisted/pre-ipo shares with as low as 25-50k depending upon the share.
- You can download the NSDL or CDSL application and login into the account and check whether the shares have been credited or not.
- Credit of Unlisted Shares/Pre-IPO shares can be checked in brokers application as well but it takes T+2 days to show the shares.
- The value of share in unlisted space is determined in the same way as it is done in listed market. Demand and supply decide the price of any share. If the demand more than the supply, then the prices of the share increases and vice versa.
- When a new shares is introduces in the unlisted space, the value of the company is decided upon the last funding raised by company. If the company hasn’t raised any funding in the past, then the valuation is decided upon the fundamentals of the company.
All the transactions are done DEMAT to DEMAT. All the unlisted shares traded with us are available in demat accounts and are transferred to your demat within 24 hours of payment.
API Holdings Ltd is the parent company of PharmEasy, the largest digital healthcare provider in India, according to Redseer Report.
Yes, the unlisted shares of API Holdings you can buy as demat form just like listed shares. In your demat account, you can buy and store them.
You can buy Pharmeasy unlisted shares easily from BharatInvest.
Pharmeasy acquired rival e-pharmacy company Medlife for an undisclosed amount in May 2021. The company acquired a 66.1% stake in diagnostics chain Thyrocare for ₹4,546 crore (US$613.5 million) in June 2021.
Pharmeasy said, the IPO was filed on 11th November 2021. It will raise funds from fresh equity issuance. Through private placement for a total amount of RS 6250 Crores, the company is talking with its banker to conduct pre-IPO fundraising.
To buy unlisted shares in India, You must have the following documents:
- CML: A copy of the Client Master List (CML).
- PAN: A copy of the Pan (Permanent Account Number) Card.
- CC: A canceled cheque from the NRO account is required to confirm your account details and validation.
Your share will be credited to your demat account within 24 hours of payment.
Bharatinvest is India’s leading investment bank. Here you can invest unlisted, pre-ipo or delisted shares of PHARMEASY (API HOLDINGS) at best price. At Bharatinvest, you will get all the updates regarding PHARMEASY (API HOLDINGS) unlisted share price, IPO news, IPO price, GMP, PHARMEASY (API HOLDINGS) share news, events, dividends, company related news, ISIN, lot size, Financials ( PHARMEASY (API HOLDINGS) Profit and loss statement, PHARMEASY (API HOLDINGS) Balance Sheet, PHARMEASY (API HOLDINGS) cash flow statement ), Peer comparision and analyst views. Investing in PHARMEASY (API HOLDINGS) share before ipo can help you invest in shares when they are available at low prices. Holding them on long term basis will help you create wealth in long term and enjoy compounding benefits. Our investors have made an average 250% returns by investing in pre-ipo shares. Buy PHARMEASY (API HOLDINGS) unlisted or Pre-ipo share at best price from our tech-platform today. You can connect with our expert financial advisors for any guidance.